China blood product industry report, 2015 2018

China Blood Product Industry

Report, 2015-2018

Apr. 2015

METHODOLOGY

Both primary and secondary research methodologies were used

in preparing this study. Initially, a comprehensive and exhaustive

search of the literature on this industry was conducted. These

sources included related books and journals, trade literature,

marketing literature, other product/promotional literature, annual

reports, security analyst reports, and other publications.

Subsequently, telephone interviews or email correspondence

was conducted with marketing executives etc. Other sources

included related magazines, academics, and consulting

companies.

INFORMATION SOURCES

The primary information sources include Company Reports,

and National Bureau of Statistics of China etc.

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant

competitor information, analysis, insight and projection on the

competitive pattern and key companies in the industry, crucial to the

development and implementation of effective business, marketing and

R&D programs.

REPORT OBJECTIVES

To establish a comprehensive, factual, annually updated and cost-

effective information base on market size, competition patterns,

market segments, goals and strategies of the leading players in the

market, reviews and forecasts.

To assist potential market entrants in evaluating prospective

acquisition and joint venture candidates.

To complement the organizations’ internal competitor information

gathering efforts with strategic analysis, data interpretation and

insight.

To suggest for concerned investors in line with the current

development of this industry as well as the development tendency.

To help company to succeed in a competitive market, and

understand the size and growth rate of any opportunity.

Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● [email protected]

Copyright 2012 ResearchInChina

Abstract

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted

from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product

enterprises.

Amid the industrial prosperity and favorable policies, China’s

production-use plasma volume broke through 4,000 tons and the

total lot release volume jumped by 15% year on year to 52.4 million bottles in 2014. By lot release volume, human albumin, human

rabies immunoglobulin, human immunoglobulin (ph4) for

intravenous injection and tetanus immunoglobulin were the most popular blood products in China in 2014, accounting for 59.8%,

14.6%, 13.6% and 4.1% of the total lot release volume respectively.

At the same time, the supply and R & D capabilities of human blood

coagulation factor VIII, human prothrombin complex and other small products in rigid demand have been intensified in recent years. In

2014, the lot release volume of the above two products ascended

by 43.9% and 46.3% year on year respectively. Chengdu Rongsheng, Guangdong Danxia, Yuanda Shuyang, Shanxi

Kangbao and other enterprises obtained clinical approval for their

human blood coagulation factor VIII in 2014.Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080

Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● [email protected]

Copyright 2012ResearchInChina

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou

Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant

capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry,

contributing 61.3% to China’s production-use plasma volume and 33.6% to China’s blood product revenue in 2014.

Shanghai RAAS turns to be a Chinese blood product leader through two acquisitions. In 2014, it took over Banghe Pharmaceutical (now

known as Zhengzhou RAAS) and TONROL for RMB1.8 billion and RMB4.758 billion separately, so that the blood product varieties of the

company increased from 7 to 11, the number of plasma collection stations rose from 12 to 28, and its plasma collection capacity expanded

from 400 tons to 900 tons.

China Blood Product Industry Report, 2015-2018 focuses on the followings:

Market characteristics, operating environments, status quo, etc. of China blood product industry;

Supply and demand, competitive landscape, import & export, development forecast, etc. of China blood product industry;

Supply and demand, competitive landscape, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for

intravenous injection, blood coagulation factor and tetanus human immunoglobulin.

Operation, blood product business and development prospects of 12 major Chinese blood product companies.


Copyright 2012ResearchInChina

1. Overview of Blood Product Industry

1.1 Definition

1.2 Classification

1.3 Recombinant Blood Products

1.4 Industry Chain

1.5 Features

2. Overview of China Blood Product Industry

2.1 Market Size

2.2 Status Quo

2.3 Supply and Demand

2.3.1 Supply

2.3.2 Demand

2.4 Market Competition

2.5 Operating Environment

2.5.1 International Market

2.5.2 Policy

2.5.3 Domestic Biopharmaceutical Market

2.6 Import and Export

3. Blood Product Market Segments in China

3.1 Human Albumin

3.1.1 Supply and Demand

3.1.2 Competitive Landscape

3.1.3 Development Prospect

3.2 Human Immunoglobulin (pH4) for Intravenous Injection

Table of contents



3.2.2Competitive Landscape

3.3 Blood Coagulation Factor VIII



3.3.3 Development Prospect

3.4 Hepatitis B Immunoglobulin



3.5 Human Immunoglobulin



3.6 Human Prothrombin Complex



3.7 Tetanus Immunoglobulin



3.8 Human Rabies Immunoglobulin



4. Major Chinese Manufacturers

4.1 China Biologic Products Inc. (NASDAQ: CBPO)

4.1.1 Profile

4.1.2 Operation

4.1.3 Revenue Structure

4.1.4 Customers and Suppliers

4.1.5 R & D and Investment

4.1.6 Shandong Taibang Biological Products Co., Ltd.

4.1.7 Guizhou Taibang Biological Products Co., Ltd.

4.1.8 Xi'an Huitian Blood Products Co., Ltd.

4.1.9 Prospect and Forecast

4.2 Hualan Biological Engineering Inc. (002007.SZ)

4.2.1 Profile

4.2.2 Operation


4.2.4 Gross Margin



4.2.7 Blood Products


4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)

4.3.1 Profile

4.3.2 Operation


4.3.4 Gross Margin




4.4 Beijing Tiantan Biological Products Co., Ltd. (600161.SH)

4.4.1 Profile

4.4.2 Operation



4.4.5 Gross Margin

.4.4.6 R & D and Investment

4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)


4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)

4.5.1 Profile

4.5.2 Operation


4.5.4 Gross Margin



4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)


4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)

4.6.1 Profile

4.6.2 Operation


4.6.4 Gross Margin



Table of contents



4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

4.7.1 Profile


4.8 Shanghai Institute of Biological Products Co., Ltd.

4.8.1 Profile


4.9 Shanxi Kangbao Biological Product Co., Ltd.

4.9.1 Profile


4.10 Green Cross

4.10.1 Profile


4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)

4.11.1 Profile

4.11.2 Operation

4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)

4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)

4.12.1 Profile

4. 12.2 Operation

4.12.3 Blood Products (Hebei Da’an Pharmaceutical Co., Ltd.)

5. Summary and Forecast

5.1 Company Analysis

5.2 Forecast

• Basic Composition of Blood

• Plasma Protein Separation Procedure

• Classification and Efficacy of Blood Products

• Comparison between Gene Recombinant Blood Products and Traditional Blood Products

• Comparison between Chinese and Overseas Recombinant Blood Products in Types

• Blood Product Industry Chain

• Time Length of Plasma Collection and Separation Process

• Comparison between Blood Product Companies and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses

• Prices of Some Blood Products in China, 2014

• Chinese Blood Product Market Size, 2003-2014

• Lot Release Volume of Blood Products in China (by Product), 2008-2014

• Blood Product Structure in China (by Lot Release Volume), 2009-2014

• Annual Production-use Plasma Volume in China, 2002-2014

• Geographical Distribution of Plasma Collection Stations in China by the End of 2014

• Main Blood Products with Medical Insurance Coverage in China

• Comparison between China and Developed Countries in Per Capita Consumption of Blood Products

• Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Manufacturers in China, 2014

• Product Line Comparison between Blood Product Manufacturers in China

• Competitive Landscape of Global Blood Product Enterprises, 2013

• Product Structure of Global Blood Products

• Blood Products Available in Foreign Countries

• Global Blood Product Manufacturers

• Major Policies on Blood Products in China

• Policies on Maximum Retail Prices of Drugs in China, 2014

Selected Charts


• Lot Release Volume of Imported Human Albumin in China, 2008-2014

• Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014

• Ratio of Domestically-produced to Imported Human Albumin in China (by Lot Release Volume), 2007-2014

• Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2014

• Consumption of Human Immunoglobulin (pH4) for Intravenous Injection Per 1,000 People by Country, 2013

• Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014

• Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2014

• Price Comparison between Chinese and Overseas Human Immunoglobulin (pH4) for Intravenous Injection

• Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2014

• Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2014

• Market Share of Major Human Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2014

• Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII

• Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries

• Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2014

• Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014

• Prices of Human Immunoglobulin in China by Dosage, 2014

• Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2014

• Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014

• Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2014

• Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2014

• Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2014

• Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014

• Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2014

• Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014

Selected Charts


• Equity Structure of China Biologic Products by the End of 2014

• Distribution of Blood Product Production Bases and Plasma Stations of China Biologic Products, 2014

• Revenue and Operating Income of China Biologic Products, 2007-2014

• Gross Margin of China Biologic Products, 2011-2014

• Revenue of China Biologic Products by Product, 2011-2014

• Revenue Structure of China Biologic Products by Product, 2010-2014

• Revenue of China Biologic Products from Top 5 Customers and % of Total Revenue, 2008-2014

• R&D Costs and % of Total Revenue of China Biologic Products, 2010-2014

• New Products of China Biologic Products under Research by the End of 2014

• Lot Release Volume of Blood Products of Shandong Taibang, 2008-2014

• Lot Release Volume of Blood Products of Guiyang Qianfeng, 2008-2014

• Lot Release Volume of Blood Products of Xi’an Huitian Blood Products, 2008-2014

• Revenue and Operating Income of China Biologic Products, 2014-2018E

• Revenue and Operating Income of Hualan Biological, 2007-2014

• Revenue of Hualan Biological by Sector, 2007-2014

• Gross Margin of Hualan Biological by Product, 2007-2014

• Revenue of Hualan Biological from Top 5 Customers and % of Total Revenue, 2007-2014

• Procurement of Hualan Biological from Top Five Suppliers and % of Total Procurement, 2007-2014

• Name List and Procurement of Hualan Biological's Top 5 Suppliers, 2014

• R&D Costs and % of Total Revenue of Hualan Biological, 2007-2014

• Varieties and Specifications of Blood Products of Hualan Biological

• Plasma Collection Station Distribution of Hualan Biological by the End of 2014

• Lot Release Volume of Blood Products of Hualan Biological, 2008-2014

• Revenue and Gross Margin of Blood Products of Hualan Biological, 2007-2014

• Revenue and Gross Margin of Hualan Biological by Product, 2007-2014

Selected Charts


• Revenue and Operating Income of Hualan Biological, 2014-2018E

• Distribution of Plasma Collection Stations of Shanghai RAAS by the End of 2014

• Revenue and Operating Income of Shanghai RAAS, 2008-2014

• Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2014

• Lot Release Volume of TONROL's Blood Products, 2008-2014

• Operating Revenue of Shanghai RAAS by Product, 2008-2014

• Revenue of Shanghai RAAS by Region, 2008-2014

• Gross Margin of Shanghai RAAS by Product, 2008-2014

• Revenue of Shanghai RAAS from Top 5 Customers and % of Total Revenue, 2007-2014

• Procurement of Shanghai RAAS from Top 5 Suppliers and % of Total Procurement, 2007-2014

• R&D Costs and % of Total Revenue of Shanghai RAAS, 2007-2014

• Revenue and Operating Income of Shanghai RAAS, 2014-2018E

• Revenue and Profit of Tiantan Biological's Subsidiaries, 2014

• Revenue and Operating Income of Tiantan Biological, 2007-2014

• Revenue of Tiantan Biological by Sector, 2007-2014

• Revenue of Tiantan Biological by Region, 2007-2014

• Procurement of Tiantan Biological from Top 5 Suppliers and % of Total Procurement, 2008-2014

• Revenue of Tiantan Biological from Top 5 Customers and % of Total Revenue, 2008-2014

• Gross Margin of Tiantan Biological by Sector, 2008-2014

• R&D Costs and % of Total Revenue of Tiantan Biological, 2009-2014

• Distribution of Blood Plasma Collection Stations of Tiantan Biological by the End of 2014

• Revenue and Gross Margin of Blood Products of Tiantan Biological, 2007-2014

• Lot Release Volume of Blood Products of Chengdu Rongsheng and Tiantan Biological, 2008-2013

• Revenue and Operating Income of Tiantan Biological, 2014-2018E

• Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2014

Selected Charts


• Operating Revenue of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2014

• Gross Margin of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2014

• Revenue of Zhenxing Biopharmaceutical and Chemical from Top 5 Customers and % of Total Revenue, 2009-2014

• Procurement of Zhenxing Biopharmaceutical and Chemical from Top 5 Suppliers and % of Total Procurement, 2013

• R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2014

• Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2014

• Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by Jun 2014

• Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2014

• Revenue and Gross Margin of Blood Products Business of Zhenxing Biopharmaceutical and Chemical, 2009-2014

• Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2018E

• Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2014

• Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2014

• Revenue of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2014

• Lot Release Volume of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2014

• Operating Revenue of Jiangxi Boya Bio-Pharmaceutical by Region, 2009-2014

• Gross Margin of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2014

• Revenue of Jiangxi Boya Bio-Pharmaceutical from Top 5 Customers and % of Total Revenue, 2009-2013

• Name List and Revenue Contribution of Top 5 Customers of Jiangxi Boya Bio-Pharmaceutical, 2014

• Procurement of Jiangxi Boya Bio-Pharmaceutical from Top 5 Suppliers and % of Total Procurement, 2009-2014

• R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2014

• Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2014-2018E

• Distribution of Blood Plasma Collection Stations of Yuanda Shuyang by the End of 2014

• Lot Release Volume of Blood Products of Yuanda Shuyang, 2008-2014

• Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2014

• Distribution of Blood Plasma Collection Stations of CNBG Shanghai Institute of Biological Products by the End of 2014

Selected Charts


• Distribution of Blood Plasma Collection Stations of Shanxi Kangbao Biological Product by the End of 2014

• Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2014

• Distribution of Blood Plasma Collection Stations of Green Cross China by the End of 2014

• Lot Release Volume of Blood Products of Green Cross China, 2008-2014

• Revenue and Operating Income of Humanwell Healthcare (Group), 2009-2014

• Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2014

• Production Industry Layout of Walvax Biotechnology

• Revenue and Operating Income of Walvax Biotechnology, 2009-2014

• Revenue of Walvax Biotechnology by Sector, 2009-2014

• Distribution of Plasma Stations of Major Blood Products Manufacturers in China by Dec 2014

• Production-use Plasma Volume of Major Blood Product Manufacturers in China, 2014

• Blood Product Revenue of Major Blood Product Manufacturers in China, 2011-2014

• Main M & A Cases in China Blood Product Industry, 2008-2014

• Chinese Blood Product Market Size, 2013-2018E

• Gross Margin of Major Blood Products Manufacturers in China, 2011-2014

Selected Charts


You can place your order in the following alternative ways:

1.Order online at www.researchinchina.com

2.Fax order sheet to us at fax number:+86 10 82601570

3. Email your order to: [email protected]

4. Phone us at +86 10 82600828/ 82601561

Party A:Name:Address:Contact Person: TelE-mail: Fax

Party B:Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina)Address: Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18,

Suzhou Street, Haidian District, Beijing, China 100080Contact Person:

Liao Yan Phone:

86-10-82600828

E-mail: [email protected] Fax: 86-10-82601570Bank details:

Beneficial Name: Beijing Waterwood Technologies Co., LtdBank Name: Bank of Communications, Beijing BranchBank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,BeijingBank Account No #: 110060668012015061217Routing No # : 332906Bank SWIFT Code: COMMCNSHBJG

Title Format Cost

Total

Choose type of format

PDF (Single user license) …………..2,500 USD

Hard copy ………………….……. 2,650 USD

PDF (Enterprisewide license)…....... 3,800 USD

※ Reports will be dispatched immediately

once full payment has been received.

Payment may be made by wire transfer or

credit card via PayPal.

How to Buy


http://www.researchinchina.com/

mailto:[email protected]

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

Multi-users market reports

Database-RICDB

Custom Research

Company Search

RICDB (http://www.researchinchina.com/data/database.html ), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at:


RICDB service

http://www.researchinchina.com/data/database.html

China blood product industry report, 2015 2018

Healthcare

Transcript of China blood product industry report, 2015 2018